October 28 2013 – Ambrisentan (Letairis) stopped early in IPF trial (Annals Int Med)

Ambrisentan (Letairis) stopped early in IPF trial

A large phase III randomized trial testing Ambrisentan (Letairis) for early idiopathic pulmonary fibrosis was stopped early after an interim analysis of the data showed possible harm. The results were reported in Annals of Internal Medicine.

Patients being treated with Letairis had more evidence of progression of idiopathic pulmonary fibrosis and were hospitalized more often, including diagnoses of acute exacerbations of IPF and pneumonia. There were 492 patients in the trial, at 136 clinical sites around the world.

Read the entire article at:

http://pulmccm.org/2013/randomized-controlled-trials/ambrisentan-letairis-stopped-early-ipf-trial-annals-int-med/?art

For more information about Idiopathic Pulmonary Fibrosis please visit our websitewww.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

This entry was posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Longfibrose, Lung Cancer, Lungen Fibrose, Medical, Pulmonary Fibrosis and tagged , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>